Cianna touts breast brachytherapy results

Breast brachytherapy firm Cianna Medical is highlighting results of a retrospective study of breast cancer patients with ductal carcinoma in situ (DCIS) who were treated with the company's strut-adjusted volume implant (SAVI) breast brachytherapy system.

Treatment with the SAVI system produced recurrence rates equivalent to those expected for whole-breast irradiation with similar follow-up, according to Dr. John Einck, of the University of California, San Diego's Moores Cancer Center, and colleagues.

The researchers reported on 248 DCIS patients treated from 2007 to 2011. Patients were stratified by age at the time of treatment completion (≥ 60 years, ≥ 50 to < 60 years, and < 50 years); local recurrence rates for each group were 1.3%, 1.1%, and 5.6%, respectively. All three groups had median follow-up greater than two years.

For the entire cohort, there were five ipsilateral breast cancer recurrences, for a 1.7% recurrence rate, the researchers found.

Einck's team used data from the SAVI Collaborative Research Group (SCRG), which studies the long-term outcomes of women treated with strut-based brachytherapy. The findings will be presented at the upcoming American Brachytherapy Society annual meeting in Orlando, FL, Cianna Medical said.

Page 1 of 461
Next Page